Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3

Table 3 Efficacy endpoints at week 16 by anti-TNF status

Endpoints	Secukinumab IV-300 mg	Secukinumab IV-150 mg	Placebo
Anti-TNF-naïve	N = 57	N = 57	N = 59
ASAS20, n (%)	37 (64.9)^§	36 (63.2)^‡	23 (39.0)
ASAS40, n (%)	25 (43.9)^‡	25 (43.9)^‡	14 (23.7)
hsCRP (post-baseline/baseline ratio), LS mean change ± SE	0.43 ± 1.1^*	0.51 ± 1.1^†	0.91 ± 1.1
ASAS 5/6, n (%)	24 (42.1)^‡	26 (45.6)^§	11 (18.6)
BASDAI, LS mean change ± SE	-3.2 ± 0.3^§	-2.6 ± 0.3	-1.9 ± 0.3
ASAS partial remission, n (%)	12 (21.1)^§	6 (10.5)	1 (1.7)
Anti-TNF-IR	N = 19	N = 17	N = 17
ASAS20, n (%)	9 (47.4)	7 (41.2)	5 (29.4)
ASAS40, n (%)	7 (36.8)	5 (29.4)	2 (11.8)
hsCRP (post-baseline/baseline ratio), LS mean change ± SE	0.57 ± 1.2^§	0.58 ± 1.3^§	1.5 ± 1.2
ASAS 5/6, n (%)	6 (31.6)^‡	5 (29.4)^‡	0
BASDAI, LS mean change ± SE	-1.8 ± 0.6	-2.2 ± 0.6	-0.9 ± 0.6
ASAS partial remission, n (%)	4 (21.1)	1 (5.9)	0

Non-responder imputation (binary variables) and mixed-model repeated measures (continuous variables) analyses are presented
TNF tumor necrosis factor, N number of patients, ASAS Assessment of SpondyloArthritis international Society, hsCRP high-sensitivity C-reactive protein, LS least squares, SE standard error, BASDAI Bath Ankylosing Spondylitis Disease Activity Index
^‡ P < 0.05, ^§ P < 0.01, ^† P < 0.001, ^* P < 0.0001 vs placebo. P-values are unadjusted

ISSN: 1478-6362